Examorelin · HEX
Most potent GHRP — maximum GH release, cardiac benefits.
FDA
Research Only
WADA
Banned
HALF-LIFE
~2–3 hours
ROUTE
SubQ injection
SCHEDULE
2–3× daily
In Plain English
Most potent GHRP — maximum GH release, cardiac benefits.
Status & Legality
NATTY?
Not NattyWADA banned substance. Tested athletes will fail.
FDA
Research OnlyFor research purposes only. Not FDA approved.
WADA
BannedOn WADA prohibited list. Use disqualifies in tested sports.
COMPOUNDING
Not from pharmaciesNot available from licensed compounding pharmacies.
PRESCRIBED
Not prescribedNot prescribed in conventional medicine.
ROUTE
SubQ injectionAdministration via subq injection.
GH stimulation
Cardiac protection
Anti-aging
Muscle growth
Hexarelin is the most potent GHRP available, producing the strongest GH pulses of any secretagogue. It also has unique direct cardiac protective effects independent of GH — it binds to cardiac GHS receptors and has shown cardioprotective properties in ischemia models. Desensitization occurs faster than with Ipamorelin.
Cortisol and prolactin elevation
Water retention
Fatigue
Headache
Rapid desensitization with continuous use
Running longer than 4–6 weeks continuously — Hexarelin desensitizes faster than any other GHRP; the mandatory off-cycle is not optional
Using it as a starter GHRP — too potent for beginners; Ipamorelin is the appropriate starting point
Ignoring the cardiac receptor binding — those with cardiac history should approach this compound with caution and physician oversight
Cardiac medications — Hexarelin's unique cardiac GHS receptor binding warrants caution for anyone with cardiac conditions
Insulin — significant GH elevation affects glucose; monitor during cycles
Other GHRPs — don't stack; pick one GHRP and pair it with a GHRH instead
Hexarelin is the most potent GHRP but burns out the fastest. Short cycles with mandatory breaks are built into the biology, not optional. Its unique cardiac receptor binding is one of the most interesting aspects in longevity research — but it also means anyone with cardiac history needs to be cautious and work with a physician.
Stats
Sources & Studies
Torsello A. et al., Eur J Pharmacol, 1997